BIO vs NAGE: fair value comparison
Bio-Rad Laboratories, Inc. and Niagen Bioscience, Inc. · Updated 2026-10-19
NAGE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, NAGE currently ranks higher by quality score.
| BIO | NAGE | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $355.57 | $2.49 |
| 12-month range | $241.71–$390.34 | $2.49–$7.60 |
| Rank by discount to fair value | #80 of 108 Healthcare | — |
| Rank by quality score | #36 of 301 Healthcare | #35 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Downtrend |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: BIO fair value analysis · NAGE fair value analysis